Amplyx laid out a promising path to a pivotal antifungal drug trial, and now Pfizer is scooping it all up in a buyout
Just 9 months after Amplyx laid out promising Phase II data for their lead antifungal, Pfizer is stepping out of the syndicate that backed the biotech and swooping in with a deal to buy out the works as the pharma giant picks up the ball and preps for a pivotal run at a breakthrough approval.
Weeks before the readout last year, Pfizer stepped in to help with a $53 million C round extension, which brought total funding at the biotech to $140 million. And while there are no terms in the buyout statement, that figure provides an idea of the multiple millions the pharma giant paid for the clinical-stage company.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.